Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department

D. Dantas Barreto Rodrigues (Braga, Portugal), C. Lacerda (Braga, Portugal), F. Aguiar (Braga, Portugal), M. Araújo (Braga, Portugal), D. Pimenta (Braga, Portugal), L. Ferreira (Braga, Portugal)

Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Session: Real-world data and registries of thoracic oncology
Session type: E-poster session
Number: 1693
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Dantas Barreto Rodrigues (Braga, Portugal), C. Lacerda (Braga, Portugal), F. Aguiar (Braga, Portugal), M. Araújo (Braga, Portugal), D. Pimenta (Braga, Portugal), L. Ferreira (Braga, Portugal). Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department. 1693

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: